Non-Antibody Protein Scaffolds Market

Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030

  • Lowest Price Guaranteed From USD 2,499

  • Pages
    247

  • View Count
    12380

Non-Antibody Protein Scaffolds Market Overview

The global non-antibody protein scaffolds drugs / diagnostics market is expected to be worth $6.2 billion by 2030, representing a CAGR of of 42% during the forecast period. Monoclonal antibodies have been in use for more than two decades. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious diseases. However, despite their clinical and commercial successes, these therapies are known to have certain drawbacks that have had an impact on their overall efficacy, thereby, limiting their therapeutic potential. These drawbacks are related to their inherent structural complexities, high manufacturing costs, difficulties in formulation and insufficient understanding of their precise in vivo mechanisms of action.

The above-mentioned limitations have prompted researchers to identify alternative protein scaffold based therapeutic strategies. Amongst other novel formats, non-antibody protein scaffolds have emerged as viable alternatives, having the capability to address the existing challenges associated with classical antibody based therapies. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. Presently, there is one approved product (Kalbitor®), and several non-antibody protein scaffold based product candidates that are being developed across various clinical and preclinical stages.Monoclonal antibodies have been in use for more than two decades. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious diseases. However, despite their clinical and commercial successes, these therapies are known to have certain drawbacks that have had an impact on their overall efficacy, thereby, limiting their therapeutic potential. These drawbacks are related to their inherent structural complexities, high manufacturing costs, difficulties in formulation and insufficient understanding of their precise in vivo mechanisms of action.

Scope of the Report

The Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030’ report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an elaborate discussion on the likely future potential of this upcoming market. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry. Amongst other elements, the report features:

  • An overview of the current market landscape, featuring comprehensive list of active industry / non industry players, and detailed analysis of non-antibody protein scaffold based product candidates, based on phase of development (clinical and preclinical / discovery), target therapeutic area(s), end-use (therapeutic agents, diagnostic imaging agents and diagnostic tests), type of scaffold format, route of administration (intravenous, subcutaneous, and intravitreal) and non-antibody protein scaffold technology used.
  • A review of the various non-antibody protein scaffolds that are presently available for the development of therapeutics / diagnostics, highlighting information on their developers, and structural and pharmacokinetic features. Specifically, for each scaffold type, we have captured information on size, origin of parent protein, structure, mode of randomization of scaffolds and number of disulfide bonds, type of production system used, method of selection, in vitro half-life and melting temperature.
  • A detailed comparative analysis of various non-antibody protein scaffolds, featuring two schematic representations, including [A] an insightful 2 X 2 analysis, to assess the technical strength of the non-antibody protein scaffolds, based on product competitiveness and pipeline strength, and [B] a spider-web analysis, highlighting the popularity of non-antibody protein scaffolds (those that have products in phase I and higher stages of clinical). The analysis was based on various parameters, such as the pipeline strength (number of drugs in both preclinical / clinical stages of development), end-use, number of related publications, target indications and technical strength.
  • Comprehensive profiles of marketed and clinical stage (phase I/II and above) non-antibody protein scaffold based drugs / diagnostics, highlighting details of the product, a brief history of development, mechanism of action, non-antibody protein scaffold technology used, manufacturing details, current status of development, information on clinical studies (including key clinical trial results) and target patient population. Each profile also features information on the developer, including an overview of the company, information on its finances and funding (if available), and an informed future outlook.
  • An analysis of the partnerships that have been inked between stakeholders in the industry in the recent past, covering R&D collaborations, product / technology licensing agreements, product development / commercialization agreements, mergers / acquisitions, clinical trial collaborations, manufacturing agreements and service agreements.
  • An in-depth analysis of the product pipeline, featuring an elaborate funnel analysis, highlighting the most popular targets being considered for therapeutic, as well as diagnostic purposes, along with the formats used and highest phase of development. It includes a grid analysis, representing the distribution of non-antibody protein scaffold based products (on the basis of their end-use) across various target therapeutic areas and different stages of development.
  • A detailed analysis of the developer companies, featuring three schematic representations; these include [A] a logo landscape of the various industry and non-industry players involved in the development of non-antibody protein scaffold based products, distributed on the basis of the phase of development of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, and [C] a bubble analysis comparing the leading players engaged in the generation of drugs / diagnostics, on the basis of parameters such as clinical activity (based on the number of drug candidates developed by a particular company, across different phases of development), number of partnerships established (between 2012 and 2017) and the size of the developer company.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the non-antibody protein scaffolds market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. In addition, we have provided the likely distribution of the market based on end-use (therapeutic agents and diagnostic agents), key therapeutic areas (genetic disorders, eye disorders, autoimmune disorders, oncology and others), and non-antibody protein scaffold technologies. To account for the uncertainties associated with the development of non-antibody protein scaffold based drugs / diagnostics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. These include Alastair Smith (CEO, Avacta), Kyu-Tae-Kim (Director, AbClon), Ratmir Derda (Assistant Professor, University of Alberta) and Aditya Pandey (Postdoctoral Fellow, University of Toronto). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com